| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Reata Pharmaceuticals Inc (NASDAQ: RETA)
RETA Technical Analysis
5
| As on 9th Jun 2023 RETA STOCK Price closed @ 93.80 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 29.68 & Strong Buy for SHORT-TERM with Stoploss of 27.77 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RETASTOCK Price
| Open | 93.96 | Change | Price | % |
| High | 94.86 | 1 Day | -0.30 | -0.32 |
| Low | 92.86 | 1 Week | 3.75 | 4.16 |
| Close | 93.80 | 1 Month | -4.43 | -4.51 |
| Volume | 619200 | 1 Year | 65.32 | 229.35 |
| 52 Week High 105.37 | 52 Week Low 19.32 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| RETA Daily Charts |
RETA Intraday Charts |
Whats New @ Bazaartrend |
RETA Free Analysis |
|
|
RETA Important Levels Intraday
| RESISTANCE | 97.65 |
| RESISTANCE | 96.42 |
| RESISTANCE | 95.65 |
| RESISTANCE | 94.89 |
| SUPPORT | 92.71 |
| SUPPORT | 91.95 |
| SUPPORT | 91.18 |
| SUPPORT | 89.95 |
RETA Forecast April 2024
| 4th UP Forecast | 107.25 |
| 3rd UP Forecast | 102.94 |
| 2nd UP Forecast | 100.27 |
| 1st UP Forecast | 97.6 |
| 1st DOWN Forecast | 90 |
| 2nd DOWN Forecast | 87.33 |
| 3rd DOWN Forecast | 84.66 |
| 4th DOWN Forecast | 80.35 |
RETA Weekly Forecast
| 4th UP Forecast | 106.94 |
| 3rd UP Forecast | 102.73 |
| 2nd UP Forecast | 100.12 |
| 1st UP Forecast | 97.52 |
| 1st DOWN Forecast | 90.08 |
| 2nd DOWN Forecast | 87.48 |
| 3rd DOWN Forecast | 84.87 |
| 4th DOWN Forecast | 80.66 |
RETA Forecast2024
| 4th UP Forecast | 263.8 |
| 3rd UP Forecast | 209.28 |
| 2nd UP Forecast | 175.58 |
| 1st UP Forecast | 141.88 |
| 1st DOWN Forecast | 45.72 |
| 2nd DOWN Forecast | 12.02 |
| 3rd DOWN Forecast | -21.68 |
| 4th DOWN Forecast | -76.2 |
Reata Pharmaceuticals Inc ( NASDAQ USA Symbol : RETA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RETA Business Profile
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Address: 5320 Legacy Drive, Plano, TX, United States, 75024
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service